Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010095 | 0.91 | PTGDR2 (0.55) | PTGDR2TBXA2RPTGDRHIF1AEPAS1 | |
| SCHEMBL1008918 | 0.82 | PTGDR2 (0.46) | PTGDR2TBXA2RPTGDRRAB9A | |
| SCHEMBL15746436 | 0.81 | PTGDR2 (0.47) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL1010589 | 0.81 | PTGDR2 (0.50) | PTGDR2TBXA2RPTGDRKCNQ3KCNQ2 | |
| SCHEMBL8739267 | 0.80 | SMN1; SMN2 (0.45) | PTGDR2NPC1RAB9A | |
| SCHEMBL8739132 | 0.79 | EGFR (0.49) | PTGDR2NPC1RAB9A | |
| SCHEMBL1008787 | 0.77 | PTGDR2 (0.55) | PTGDR2NPC1RAB9A | |
| SCHEMBL1010884 | 0.77 | PTGDR2 (0.52) | PTGDR2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL8739184 | 0.74 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL8739349 | 0.73 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDRTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | HRH2, HRH1, HRH4 | PTGDR2 11/4885TBXA2R 20/4885PTGDR 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.